Closed
Plasma For Fractionation
Descriptions
The medicines and healthcare products regulatory agency is in the process of reviewing the risk assessment associated with the use of UK plasma for the production of plasma derived medicines, including the production of hyperimmune immunoglobin (IG) for Covid-19 patients. NHSBT wishes to understand in more detail the implications for its processes and systems were NHSBT required to supply convalescent plasma for the production of Covid-19 hyperimmune IG, or to supply domestic UK plasma for the fractionation supply chain more widely.
Timeline
Pretender :
Not Identified
Published Date :
Deadline :
Contract Start :
Contract End :
Tender Regions
CPV Codes
71900000 - Laboratory services
71600000 - Technical testing, analysis and consultancy services
33696200 - Blood-testing reagents
33141520 - Plasma extracts
85146000 - Services provided by blood banks
85111810 - Blood analysis services
71632000 - Technical testing services
Workflows
Status :
Assign to :
Tender Progress :
Details
Notice Type :
Tender Identifier :
TenderBase ID :
Low Value :
High Value :
Region :
Attachments :
Buyer Information
Address :
Website :
Procurement Contact
Name :
Designation :
Phone :
Email :
Possible Competitors
1 Possible Competitors
